Data / Drug companies / Oryza Pharmaceuticals Inc.
Oryza Pharmaceuticals Inc.: 22 products in the FDA NDC directory, labeler code 72516
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Oryza Pharmaceuticals Inc. (labeler code 72516) lists 22 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 22 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 18, 2026.
The request: Watch Oryza Pharmaceuticals Inc. (FDA labeler code 72516): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72516
- Products in commercial distribution
- 22
- Packages
- 39
- Finished drugs by generic name
- 6
- Prescription products
- 22
- Over the counter products
- 0
- Controlled substance products
- Schedule II 6
- Flagged as original packager
- 18 of 18 products that carry the flag
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- September 6, 2019
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 21 | 95.5% |
| Other unapproved drugs | 1 | 4.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 22 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Metoprolol succinate | 8 | 46 |
| Carbamazepine | 2 | 52 |
| Ticagrelor | 2 | 32 |
| Bupropion hydrochloride | 2 | 67 |
| Oseltamivir phosphate | 1 | 37 |
| Papaverine hydrochloride | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 12 | 54.5% |
| Tablet | 8 | 36.4% |
| Powder, for suspension | 1 | 4.5% |
| Injection, solution | 1 | 4.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| beta-Adrenergic Blocker | 8 |
| Central Nervous System Stimulant | 6 |
| Mood Stabilizer | 2 |
| P2Y12 Platelet Inhibitor | 2 |
| Aminoketone | 2 |
| Neuraminidase Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Carbamazepine ER | 72516-021 | Tablet, extended release | Generic drugs (ANDA) | May 18, 2026 |
| Carbamazepine ER | 72516-020 | Tablet, extended release | Generic drugs (ANDA) | May 18, 2026 |
| Metoprolol succinate | 72516-025 | Tablet, extended release | Generic drugs (ANDA) | May 15, 2026 |
| Ticagrelor | 72516-017 | Tablet | Generic drugs (ANDA) | December 1, 2025 |
| Oseltamivir Phosphate for Oral Suspension | 72516-029 | Powder, for suspension | Generic drugs (ANDA) | October 19, 2025 |
| Metoprolol succinate | 72516-028 | Tablet, extended release | Generic drugs (ANDA) | July 21, 2025 |
| Metoprolol succinate | 72516-027 | Tablet, extended release | Generic drugs (ANDA) | July 21, 2025 |
| Metoprolol succinate | 72516-026 | Tablet, extended release | Generic drugs (ANDA) | July 21, 2025 |
| Ticagrelor | 72516-018 | Tablet | Generic drugs (ANDA) | April 15, 2025 |
| Metoprolol Succinate | 72516-033 | Tablet, extended release | Generic drugs (ANDA) | April 27, 2022 |
| Metoprolol Succinate | 72516-032 | Tablet, extended release | Generic drugs (ANDA) | April 27, 2022 |
| Metoprolol Succinate | 72516-031 | Tablet, extended release | Generic drugs (ANDA) | April 27, 2022 |
| Metoprolol Succinate | 72516-030 | Tablet, extended release | Generic drugs (ANDA) | April 27, 2022 |
| Papaverine Hydrochloride | 72516-024 | Injection, solution | Other unapproved drugs | February 1, 2021 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate | 72516-016 | Tablet | Generic drugs (ANDA) | October 19, 2020 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate | 72516-015 | Tablet | Generic drugs (ANDA) | October 19, 2020 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate | 72516-014 | Tablet | Generic drugs (ANDA) | October 19, 2020 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate | 72516-013 | Tablet | Generic drugs (ANDA) | October 19, 2020 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate | 72516-012 | Tablet | Generic drugs (ANDA) | October 19, 2020 |
| Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate | 72516-011 | Tablet | Generic drugs (ANDA) | October 19, 2020 |
| BuPropion Hydrochloride XL | 72516-035 | Tablet, extended release | Generic drugs (ANDA) | October 1, 2020 |
| BuPropion Hydrochloride XL | 72516-036 | Tablet, extended release | Generic drugs (ANDA) | September 6, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.